Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo.
This study aimed to investigate the monoclonal antibody (mAb) 2C5 with nucleosome-restricted specificity for its ability to specifically recognize human brain tumor cells and to serve as a specific ligand for liposome targeting to brain tumor cells in vitro and in vivo. The affinity of mAb 2C5 towards brain tumor cells was tested by flow cytometry. The interaction of 2C5-immunoliposomes (ILS) with brain tumor cells in vitro was studied by fluorescence microscopy. For in vivo accumulation studies, (111)In-ILS were administered i.v. into mice bearing subcutaneously grown brain tumor. mAb 2C5 was found to be reactive against several tested brain tumor cell lines. mAb 2C5 and 2C5-ILS demonstrated enhanced cell-surface binding with CCF-STTG1,U-87 MG and LN-18 cells in vitro. 2C5-ILS displayed significantly better accumulation in the subcutaneously grown brain tumor than non-specific control IgG-ILS. mAb 2C5 specifically recognizes brain tumor cells and can serve as a ligand to target drug carriers such as liposomes to brain tumor cells in vivo.